No.
STUDY
STUDY TITLE
SAMPLE SIZE
STUDY IOR/SC
STATUS
1.
P1092
Evaluation of the Steady State Pharmacokinetics of Zidovudine, Lamivudine, Nevirapine and Lopinavir/ritonavir in Severely Malnourished HIV-infected Children Initiating HAART
15 HIV-infected and malnourished children
IOR: Dr. Maxensia Owor
SC: Dr. Phionah Kibalama
Ongoing
2.
P1078

A Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety of Immediate (Antepartum-Initiated) versus Deferred (Postpartum-Initiated) Isoniazid Preventive Therapy (IPT) Among HIV-Infected Women in High TB Incidence Settings

166 mother-infant pairs
IOR: Dr. Carolyne Onyango
SC: Dr. Enid Kabugho
  • Ongoing data cleaning to September 2018
  • Dissemination of study results to study participants ongoing
3.
P1115
Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV  Remission: A Phase I/II Proof of Concept
35-40 mother infant pairs expected to be enrolled at the MUJHU site for Cohort 1/Step 1, and 5 mother infant pairs for Cohort 1 and 2 Steps 2,3 and 4
IOR: Dr. Linda Barlow- Mosha
SC: Dr. Phionah Kibalama
  • On Hold
  • Version 2.0 Under development
4.
P1026s
Pharmacokinetic Properties of Antiretroviral Drugs during Pregnancy
15 women
IOR: Dr. Deo Wabwire
SC:Dr. Jovita Katusiime
Ongoing with expected completion  2018
5.
P1093
IMPAACT P1093: Phase I/II Multi-center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents.
40 infants
IOR: Dr. Linda Barlow-Mosha
SC: Dr. Grace Miriam Ahimbisibwe
Ongoing
No.
STUDY
STUDY TITLE
SAMPLE SIZE
STUDY IOR/SC
STATUS
6.
IMPAACT 2007
Phase I Safety and Pharmacokinetic Study of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection.
15 HIV-infected and malnourished children
IOR: Dr. Maxensia Owor
SC: Dr. Phionah Kibalama
  • Awaiting completion of regulatory process occasioned by the change of IoR.
7.
IMPAACT 2009
Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for Primary HIV Prevention during Pregnancy and Breast Feeding in Adolescents and Young Women
 
8-12  PK Component
70 for the PrEP Comparison component
 
IOR: Dr. Clemensia Nakabiito
SC: Dr. Phionah Kibalama
  • Study still in regulatory process. Site received initial approval from JCRC,
8.
IMPAACT 2010
Virologic Efficacy and Safety of Dolutegravir/Tenofovir alafenamide/Emtricitabine (DTG/TAF/FTC) vs. Efavirenz/Tenofovir disoproxil/Emtricitabine or Lamivudine (EFV/TDF/FTC or 3TC) in HIV-Infected Pregnant Women and their Infants.t
56 mother-infant pairs
IOR:Dr. Deo Wabwire
SC: Dr. Enid Kabugho
  • Study initiated on 10 April 2018.
  • 3 participants enrolled
9.
HOPE(MTN 025)
A Multi-Center, Phase 3B Open- label Follow-up trial to Assess the continued Safety of  and Adherence to a Vaginal Ring Containing Dapivirine in Women.
242 HIV-uninfected women
IOR: Dr. Brenda Gati
SC: Dr. Carolyne Akello
  • Enrollment ongoing to end of May 2018
  • Total enrolled – 176
  • Enrolled on product – 172
  • Enrolled Decliner Population – 4
  • Terminated – 87
  • In follow up - 89
10.
MTN 015
An Observational Cohort Study of Women following HIV-1 Seroconversion in Microbicide Trials.
Open sample size
Dependent on parent MTN 025 protocol
IOR: Dr. Clemensia Nakabiito
SC: Dr. Carolyne Akello
  • Ongoing
  • Enrolled = 8
  • Terminated = 1 ( early Termination)
  • In follow up,=7
No.
STUDY
STUDY TITLE
SAMPLE SIZE
STUDY IOR/SC
STATUS
11.
MTN 016
HIV Prevention Agent Pregnancy Exposure Registry
Open sample sizeDependent on parent MTN 025 protocol
IOR: Dr. Kenneth Kintu
  • Enrolled from MTN 025 = 4
  • Pending enrollment = 1
  • In follow up=4.
  • Ongoing
12.
MTN 032
Assessment of ASPIRE and HOPE Adherence
 
 
1st Phase 292nd Phase 26 women and 20 men  participants
 
IOR: Juliane Etima
SC:Dr. Carolyne Akello
  • Initiated on 20th April 2018
  • 2 participants enrolled
  • Awaiting approval for permission to contact male partners’ form
13.
Telomere
CD4-cell Telomere Length in Perinatally HIV-infected and HIV-uninfected Ugandan Youths
 
48 adolescents
IOR: Steve Bolton
SC: Dr. Hellen Kaganzi
  • Data cleaning Ongoing.
14.
PROMOTE
PROMISE Ongoing Treatment Evaluation
Participants from PROMISE,Approx. 350
IOR: Dr. Lilian Wambuzi
SC: / Dr. Catherine Nakaye
  • Ongoing, expected completion 2020
  • 352 Mothers enrolled and in follow up. Currently consenting for LOA 1 from 20 Mar 2018.
  • PROMOTE Children: 49 enrolled, 48 in follow up, 1 death
15.
Option B+
USING ENHANCED PEER GROUP STRATEGIES TO SUPPORT PREVENTION OF MOTHER TO CHILD HIV TRANSMISSION (PMTCT) OPTION B+ IN UGANDA
540
IOR: Dr. Philippa Musoke
SC: Priscilla Wavamuno / Dr. Alex Amone
  • Ongoing, expected completion June 2019
  • Enrolled 540
  • Terminated – 47
  • Follow up – 493
  • Number of FLC groups - 28
No.
STUDY
STUDY TITLE
SAMPLE SIZE
STUDY IOR/SC
STATUS
16.
Birth Defects Survaillance
Hospital –Based Birth Defects surveillance in Kampala, Uganda
Assess all live born children at birth
IOR: Dr. Philippa Musoke
SC: Dr. Daniel Mumpe
  • Ongoing surveillance of birth defects in Mulago, Nsambya, Mengo and Rubaga Hospitals
  • Over 79,000 births included in surveillance
  • Ongoing, expected completion 2020.
17.
Bone Care Study
Bone Mineral Density Among Young HIV Infected Women in Kampala-Uganda
 
 
519 women
 
IOR: Dr. Flavia Matovu
SC: Esther Isingel
  • Enrolled- 519
  • In Follow up- 474
  • Data cleaning on going
  • Ongoing, expected completion May 2019
18.
Microbiome
Modifiers of Tenofovir Exposure in the Female Genital Tract of African Women on Depo- Provera
50
IOR: Dr. Flavia Matovu
SC: Esther Isingel
  • Enrollment completed
  • Ongoing data entry and cleaning
19.
Neurodevelopment Study
Developmental, Neuropsychological and Physical Growth Outcomes among HIV Exposed Uninfected Infants who are exposed to antiretroviral drugs Protocol version 5.0, dated 12 November 2015
 
480 mother-infant pairs
 
IOR: Dr. Lilian Wambuzi
 
  • Ongoing, expected completion November 2018
20.
Shine
A randomized trial of shortening therapy for minimal tuberculosis using new WHO-recommended dosages in African and Indian HIV+ and HIV- children
370 children
IOR: Dr. Eric Wobudeya
SC: Dr. Robert Mboizi
  • Ongoing, expected completion July 2021
  • Enrolled 316
  • Follow Up – 276
  • Deaths - 11
21.
Odyssey
ODYSSEY (PENTA 50): A randomised trial of dolutegravir (DTG)-based antiretroviral therapy vs. standard of care (SOC) in children with HIV infection starting first-line or switching to second-line ART
40 children
IOR: Dr. Linda Barlow-Mosha
SC: Dr. Grace Ahimbisibwe
  • Ongoing, expected completion December 2020
  • Enrolled -48
  • Terminated – 1
  • Follow up – 47
No. STUDY STUDY TITLE SAMPLE SIZE STUDY IOR/SC STATUS
1. HI4TU
Enhanced HIV/STI and Pregnancy Prevention Study to Improve Adolescent Reproductive Health Services in Uganda
519 pregnant adolescents aged 15 through 19 years.

IOR: Prof. Florence Mirembe

SC: Dr. Carolyne Akello

  • Completed October 2017
  • Data Cleaning ongoing
Updtaes Coming Soon